Dynamk Capital Joins World-Class Syndicate of LS Investors Participating in Xcellbio’s $27.5 Series B Round

Xcell Biosciences, Inc. (“Xcellbio”), a leading developer of innovative technologies and platforms designed to further the research, development, and manufacturing of cell and gene therapies, announced $27.5 million in Series B financing led by Casdin Capital. The funds will be used to scale delivery of first-in-class platforms that enable the development of cell and gene therapies.